Presentation is loading. Please wait.

Presentation is loading. Please wait.

IISP Workshop Gaithersburg, Maryland May 23 - 24, 2006 Nanotechnology Initiative Paul F. Wambach, CIH Industrial Hygienist Office of Epidemiology and Health.

Similar presentations


Presentation on theme: "IISP Workshop Gaithersburg, Maryland May 23 - 24, 2006 Nanotechnology Initiative Paul F. Wambach, CIH Industrial Hygienist Office of Epidemiology and Health."— Presentation transcript:

1 IISP Workshop Gaithersburg, Maryland May 23 - 24, 2006 Nanotechnology Initiative Paul F. Wambach, CIH Industrial Hygienist Office of Epidemiology and Health Surveillance

2 2 Outline of Talk What is nanotechnology? What is the National Nanotechnology Initiative? ES&H Risks Risk Management Initiatives

3 3 What Is Nanotechnology?  Nanoscale research and development at dimensions of approximately 1 - 100 nanometer  Fundamentally new properties and functions because of their nanoscale structure  Ability to image, measure, model, and manipulate matter on the nanoscale  Ability to integrate those properties and functions into systems spanning from nano to macroscopic scales Corral of Fe Atoms – D. Eigler Nanoarea Electron Diffraction of DW Carbon Nanotube – Zuo, et.al

4 4 Nano Scale Engineered Materials First Generation - Small size and large surface area (nano iron) Second Generation – Novel molecules with desirable properties (carbon nanotubes) Third Generation – Self assembly modeled on biological mechanisms (virus assembled gold wire)

5 5 Unique Properties From Size 3 nm4 nm5 nm6 nm7 nm Color of fluorescence determined by size of particles Quantum Size Effect in Cadmium Selenide

6 6 Nanoscale Engineered Material Production Removing material from laser ablation reactor Material removal from HiPCO reactor

7 Single Walled Carbon Nanotubes Raw single walled carbon nanotube material. Nanotubes Nanoropes Catalyst particles Non-tubular carbon Courtesy Andrew Maynard - NIOSH

8 8 What is the NNI?  The National Nanotechnology Initiative first funded National Science Foundation in FY-01 to coordinate Federal R&D  21st Century Nanotechnology Research and Development Act, December 2003  For FY 2006, estimated R&D funding totals over $1 billion across 11 agencies; 11 additional participating agencies  For more information see the NNI strategic plan at http://www.nano.gov/NNI_Strategic_Plan_2004.pdf

9 9 DOE NNI Mission Provide the physics, chemistry, and computational tools needed to make nanotechnology possible. $1.5 billion appropriated over 4 years for building and operating 5 Nanoscale Science Research Centers at: ORNL, LBNL, ANL, BNL, SNL that will also provide access to resources at LANL. The first facility at ORNL is scheduled to be completed by September 2006 with all completed by 2008.

10 10 ES&H Risks of Nanoscale Materials Chemical reactivity of nanoscale materials different from more macroscopic form, e.g., gold Vastly increased surface area per unit mass, e.g., upwards of 100 m 2 per gram New physical forms of common chemical elements change properties, e.g. proteins Do these properties lead to new and unique health risks …?

11 11 Ultrafine Particle Toxicology Recent examination of literature indicated over 10,000 peer-reviewed papers – V. Colvin Ambient ultrafine particles are associated with adverse respiratory and cardiovascular effects in susceptible people Recent work on toxicity, fate, and transport of Teflon, metal oxides, and carbon ultrafine particles in animals are establishing the mechanisms for effects observed in humans. University of Rochester (G. Oberdorster)

12 Airborne Nanomaterials PROCESS Primary Particles Aggregates & Agglomerates Droplets Small diameter (~5 - 30 nm) High surface area Deposition throughout the respiratory tract and rapid uptake High surface area Typically ~ 100 - 1000 nm in diameter Deposition in the lung uptake by immune system cells Residue can have nanostructure And high surface area Deposition throughout the respiratory tract and gut Courtesy Andrew Maynard - NIOSH

13 13 Primary Particles Small Compared to Cells

14 14 ES&H Challenges No standard nomenclature or material specifications Hazard testing not keeping pace with materials development No exposure limits Hype – research and materials called nano to gain support Dread – exotic, unfamiliar hazard

15 15 Risk Management Initiatives DOE P 456.1 SECRETARIAL POLICY STATEMENT ON NANOSCALE SAFETY DOE and its contractors will identify and manage potential health and safety hazards and potential environmental impacts at sites... Nanoscale Science Research Centers Group NIOSH and ANSI EFCOG Occupational Safety and Health Group Nano material: Hazard Assessment, Health Risks, and Safety Analysis Process project was approved at the joint EFCOG/DOE Chemical Management Workshop, March 14-16 29 individuals have volunteered to participate.

16 16 Integrated Safety Management

17 17 Define Scope of Work What distinguishes nanotechnology from other material science projects? Nanoscale Science Research Centers will characterize and test samples of nanoscale engineered materials. Application of nanotechnology to energy and defense research and development. Pilot plant scale production operations?

18 18 Analyze Hazards Are there equipment and process materials that are unique to nanotechnology? What assumptions should be made on the hazards of untested materials? How do we interpret exposure monitoring results without exposure limits? What medical tests and examinations should be used to monitor nanotechnology workers?

19 19 Develop and Implement Hazard Controls Are facility, utility, and equipment codes and standards currently in use for materials science sufficient? Are UK Control Banding or ILO Toolkit strategies useful for health risk management? Are existing procedures sufficient for assuring visiting scientists know how to protect themselves?

20 20 Feedback and Improvement Occurrence Investigation and Reporting Definition of a nanotechnology occurrence Health Surveillance Medical Surveillance – sentinel health event or unusual pattern of injury, illness, or clinical finding Exposure Surveillance – unusual events or higher than expected exposures Health and exposure data linked to individual identifier Routine collection, analysis and dissemination of information to those who need to know

21 21 Conclusions NNI legislation has established public policy Secure the benefits of nanotechnology Manage the risks Ready, shoot, aim – Feedback is important Passive surveillance – injury, illness, and occurrence reporting – has limited ability to answer questions Active surveillance – worker registries – needed to identify potential health effects as early as possible.


Download ppt "IISP Workshop Gaithersburg, Maryland May 23 - 24, 2006 Nanotechnology Initiative Paul F. Wambach, CIH Industrial Hygienist Office of Epidemiology and Health."

Similar presentations


Ads by Google